In the current study, Imaging mass spectrometry (IMS)-based proteomic classification was used to describe proteomic differences between BRAF (v-raf murine sarcoma viral oncogene homolog B1) and NRAS (neuroblastoma RAS viral oncogene homolog) mutated MM and has expanded the knowledge currently available. The gene discussed is BRAF; the disease is Miyoshi myopathy.